Overview / Abstract: |
Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series. TNBC is an aggressive disease that disproportionately affects African American women in the United States. Treatment options are limited for TNBC compared with other types of breast cancer, but new therapies hold promise for improved patient outcomes. This activity aims to help the multidisciplinary TNBC team with practical strategies to integrate evidence-based treatment options, particularly PARPIs, into practice. |
Expiration |
Aug 03, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
0.50 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Sarah Blair, MD; Sarah Donahue, MPH, NP, AOCNP; Amir Momeni-Boroujeni, MD; Rita Nanda, MD |
Sponsors / Supporters / Grant Providers |
Supported by an independent educational grant from Gilead Sciences, Inc. |
Keywords / Search Terms |
ACHL CME, CE, Continuing Medical Education, CME/CE, Online Learning, Webcasts, Newsletter, Case Study, University of Chicago Pritzker School of Medicine Center for Continuing Medical Education, University of Chicago, triple-negative breast cancer, TNBC, Trop2, antibody drug conjugate (ADC), oncologist, oncology, breast cancer, racial disparities, estrogen, receptor, progesterone Free CE CME |